Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
Details
Publication Year 2024-07,Volume 54,Issue #7,Page 1214-1218
Journal Title
Internal Medicine Journal
Publication Type
Research article
Abstract
Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.
Publisher
Wiley
Keywords
Humans; *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Australia; Male; Middle Aged; *Protein Kinase Inhibitors/therapeutic use; Female; Treatment Outcome; Aged; Adult; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl/antagonists & inhibitors; Antineoplastic Agents/therapeutic use; Pyridazines/therapeutic use; Aged, 80 and over; Niacinamide/analogs & derivatives; Pyrazoles; asciminib; chronic myeloid leukaemia; tyrosine kinase inhibitor
Department(s)
Clinical Haematology
Open Access at Publisher's Site
https://doi.org/10.1111/imj.16446
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-30 06:26:18
Last Modified: 2024-07-30 06:34:07

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙